{"id":476666,"date":"2021-04-15T07:04:04","date_gmt":"2021-04-15T11:04:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/"},"modified":"2021-04-15T07:04:04","modified_gmt":"2021-04-15T11:04:04","slug":"syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/","title":{"rendered":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias"},"content":{"rendered":"
\n

– Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WALTHAM, Mass.<\/span>, April 15, 2021<\/span> \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1\/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021<\/span> at 8:00 a.m. ET<\/span>. SNDX-5613 is the Company’s highly selective, oral menin inhibitor.<\/p>\n

The event will feature the trial’s principal investigator, Eytan M. Stein<\/span>, M.D., Assistant Attending Physician and Director, Program for Drug Development in Leukemia, Department of Medicine at Memorial Sloan Kettering Cancer Center.<\/p>\n

\n Conference Call and Webcast Details<\/b>\n <\/p>\n

The live video webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website at\u00a0www.syndax.com<\/a>. Alternatively, the conference call may be accessed through the following:<\/p>\n

Conference ID: 3129568
Domestic Dial-in Number: (877) 474-0326
International Dial-in Number: (918) 922-6881
Live webcast: https:\/\/onlinexperiences.com\/Launch\/QReg\/ShowUUID=E0296F2E-256E-494B-A4F6-FD7220BACE26<\/a><\/p>\n

For those unable to participate in the live event, a replay will be available on the Investors section of the Company’s website,\u00a0www.syndax.com<\/a>.<\/p>\n

\n About\u00a0Syndax Pharmaceuticals, Inc.\u00a0<\/b>\n <\/p>\n

Syndax Pharmaceuticals\u00a0is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin\u2013MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.<\/p>\n

\n Syndax’s Cautionary Note on Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax’s product candidates, and the potential use of our product candidates to treat various cancer indications. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of Syndax’s collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the\u00a0U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n

\n Syndax Contacts<\/b>\n <\/p>\n

Investor Contact
Melissa Forst<\/span>
Argot Partners
melissa@argotpartners.com<\/a>\u00a0
Tel 212.600.1902<\/p>\n

Media Contact
Ted Held<\/span>
ted.held@gcihealth.com<\/a>
Tel 212.798.9842<\/p>\n

SNDX-G<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias-301269535.html<\/a><\/p>\n

SOURCE Syndax Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

– Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET – PR Newswire WALTHAM, Mass., April 15, 2021 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1\/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. ET. SNDX-5613 is the Company’s highly selective, oral menin inhibitor. The event will feature the trial’s principal investigator, Eytan M. Stein, M.D., Assistant Attending Physician and Director, … <\/p>\n

Continue reading “Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476666","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSyndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET – PR Newswire WALTHAM, Mass., April 15, 2021 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1\/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. ET. SNDX-5613 is the Company’s highly selective, oral menin inhibitor. The event will feature the trial’s principal investigator, Eytan M. Stein, M.D., Assistant Attending Physician and Director, … Continue reading "Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T11:04:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias\",\"datePublished\":\"2021-04-15T11:04:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/\"},\"wordCount\":652,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE43234&sd=2021-04-15\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/\",\"name\":\"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE43234&sd=2021-04-15\",\"datePublished\":\"2021-04-15T11:04:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE43234&sd=2021-04-15\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NE43234&sd=2021-04-15\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/","og_locale":"en_US","og_type":"article","og_title":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk","og_description":"– Event to be webcast live on Tuesday, April 20, 2021 at 8:00 a.m. ET – PR Newswire WALTHAM, Mass., April 15, 2021 \/PRNewswire\/ —\u00a0Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1\/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m. ET. SNDX-5613 is the Company’s highly selective, oral menin inhibitor. The event will feature the trial’s principal investigator, Eytan M. Stein, M.D., Assistant Attending Physician and Director, … Continue reading \"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T11:04:04+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias","datePublished":"2021-04-15T11:04:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/"},"wordCount":652,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/","name":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15","datePublished":"2021-04-15T11:04:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE43234&sd=2021-04-15"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-pharmaceuticals-to-host-conference-call-and-webcast-to-provide-updated-data-from-phase-1-portion-of-augment-101-trial-of-sndx-5613-in-patients-with-acute-leukemias\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476666"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476666\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}